Tedatioxetine

Tedatioxetine is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) that was under development by Lundbeck and Takeda Pharmaceutical Company for the treatment of major depressive disorder and generalized anxiety disorder. It was in Phase II clinical trials in 2012, but development was discontinued in 2013.

History

Tedatioxetine was first synthesized and developed by Lundbeck, a Danish international pharmaceutical company, and Takeda Pharmaceutical Company, a Japanese multinational pharmaceutical company. The drug was in Phase II clinical trials in 2012, but the development was discontinued in 2013 due to undisclosed reasons.

Pharmacology

Tedatioxetine is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI). It works by inhibiting the reuptake of serotonin, norepinephrine, and dopamine, three neurotransmitters in the brain that are linked to mood and anxiety. By inhibiting their reuptake, tedatioxetine increases the levels of these neurotransmitters in the brain, which can help to alleviate the symptoms of depression and anxiety.

Clinical Trials

Tedatioxetine was in Phase II clinical trials for the treatment of major depressive disorder and generalized anxiety disorder. However, the development of the drug was discontinued in 2013 before it could reach Phase III trials.

Discontinuation

The development of tedatioxetine was discontinued in 2013. The reasons for the discontinuation were not publicly disclosed, but it is common for drugs to be discontinued at this stage of development due to a variety of factors, including lack of efficacy, safety concerns, or strategic decisions by the developing company.

See Also

• Serotonin–norepinephrine–dopamine reuptake inhibitor
• Lundbeck
• Takeda Pharmaceutical Company
• Major depressive disorder
• Generalized anxiety disorder